All In Biotech

Drug Trial Radar · NCT05875948

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome - Acute Kidney Injury

Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

Jun 30, 2023

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
River 2 Renal Corp.Industry
Sponsor type
Industry
First posted
May 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI

Conditions

  • Hepatorenal Syndrome
  • Acute Kidney Injury

Interventions

  • R2R01Drug

    Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.

  • TerlipressinDrug

    In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL). In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Evaluation Criteria - Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug to 30 days post last dose
  2. Safety Evaluation Criteria - Change in WeightTime frame: Change from screening through Day 30
  3. Safety Evaluation Criteria - Vital Signs - Respiration RateTime frame: Change from screening through Day 30
  4. Safety Evaluation Criteria - Vital Signs - Body TemperatureTime frame: Change from screening through Day 30
  5. Safety Evaluation Criteria - Vital Signs - Continuous pulse oximetry (SpO2)Time frame: Change from baseline through Day 30
  6. Safety Evaluation Criteria - Vital Signs - Systolic Blood Pressure (SBP)Time frame: Change from screening through Day 30
  7. Safety Evaluation Criteria - Vital Signs - Diastolic Blood pressure (DBP)Time frame: Change from screening through Day 30
  8. Safety Evaluation Criteria - Vital Signs - Heart Rate (HR)Time frame: Change from screening through Day 30
  9. Safety Evaluation Criteria - ECGs - PR intervalTime frame: Change from screening to Day 14 or hospital discharge
  10. Safety Evaluation Criteria - ECGs - RR intervalTime frame: Change from screening to Day 14 or hospital discharge
  11. Safety Evaluation Criteria - ECGs - QRS durationTime frame: Change from screening to Day 14 or hospital discharge
  12. Safety Evaluation Criteria - ECGs - QT intervalTime frame: Change from screening to Day 14 or hospital discharge
  13. Safety Evaluation Criteria - ECGs - QTcF intervalTime frame: Change from screening to Day 14 or hospital discharge
  14. Safety Evaluation Criteria - ECGs - QTcB intervalTime frame: Change from screening to Day 14 or hospital discharge
  15. The incidence of RespondersTime frame: 90 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • California Pacific Medical Center

    San Francisco, California · Not yet recruiting

  • Piedmont Healthcare, Inc

    Atlanta, Georgia · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Not yet recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor Scott and White All Saints Medical Center

    Fort Worth, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.